세계의 항-D 면역글로불린 시장 보고서(2025년)
Anti-D Immunoglobulin Global Market Report 2025
상품코드 : 1810826
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,498,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,393,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,288,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

항-D 면역글로불린 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 33억 4,000만 달러로 성장할 것이며, CAGR은 6.6%에 달할 것입니다. 예측 기간 동안의 성장은 임산부 및 주산기 치료에 대한 수요 증가, 중저소득 국가에서 임산부 건강에 대한 관심 증가, 의료 인프라에 대한 투자 확대, 보편적 건강 보장 프로그램 확대, 면역글로불린 요법에 대한 규제 당국의 지원 등에 기인할 것으로 예상됩니다. 이 기간 동안 예상되는 주요 동향으로는 혈장 분획 기술의 발전, 대체 유전자재조합 항체 개발, 면역글로불린 제조 자동화 발전, 고순도 제제화 기술 도입, 콜드체인 모니터링 시스템 통합 등이 있습니다.

전 세계 출산율의 증가는 향후 항-D 면역글로불린 시장의 성장을 견인할 것으로 예상됩니다. 출산율은 인구 1,000명당 연간 출생아 수를 나타냅니다. 이 출산율은 교육 및 가족계획 서비스에 대한 접근이 제한되어 출산율 상승과 가족 수 증가로 이어지고 있습니다. 항-D 면역글로불린은 신생아의 용혈성 질환의 위험을 줄이고 임신 중 Rh 비호환성을 예방하여 이후 임신에서 더 건강한 결과를 촉진함으로써 이러한 출산율을 지원합니다. 예를 들어, 2025년 4월 미국 정부 기관인 질병통제예방센터는 2024년 출생아 수가 362만 2,673명으로 전년 대비 1% 증가했다고 보고했습니다. 이처럼 출산율의 증가는 항-D 면역글로불린 시장 확대에 박차를 가하고 있습니다.

또한, 헬스케어 인프라의 성장도 향후 항-D 면역글로불린 시장을 견인할 것으로 예상됩니다. 헬스케어 인프라에는 의료 서비스를 제공하는 데 필요한 시설, 장비, 인력, 지원 시스템이 포함됩니다. 헬스케어 인프라의 확대는 전 세계적인 인구 증가로 인한 의료 수요 증가로 인해 병원, 진료소, 자원의 추가 개발이 필요하게 될 것입니다. 의료 인프라가 개선되면, 산모 치료 접근성이 향상되고, 신생아 용혈성 질환을 예방하기 위한 선별검사 및 항-D 면역글로불린의 적시 투여가 용이해집니다. 예를 들어, 2023년 5월 영국 정부의 보건사회부는 새로운 병원 시설 건설에 270억 달러(200억 파운드) 이상을 투자할 계획을 발표했습니다. 신병원 계획에 따라 2곳의 병원이 완공되었고, 5곳의 병원이 건설 중이며, 20개 이상의 병원이 내년 말까지 완공될 예정이거나 진행 중입니다. 따라서 헬스케어 인프라의 확대가 항-D 면역글로불린 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Anti-D immunoglobulin is a specialized blood product derived from human plasma that contains antibodies targeting the RhD antigen present on red blood cells. It is produced by collecting plasma from donors sensitized to the RhD antigen, followed by purification and concentration of the specific immunoglobulin G (IgG) antibodies.

The primary product types of anti-D immunoglobulin include intramuscular and intravenous formulations. Intramuscular anti-D immunoglobulin is a plasma-derived antibody preparation administered into muscle tissue to prevent Rh incompatibility in Rh-negative individuals by neutralizing Rh-positive fetal red blood cells. These products are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used for applications including hemolytic disease of the newborn, immune thrombocytopenic purpura, antenatal and postnatal prophylaxis, among others. They serve several end users, including hospitals, clinics, blood banks, and research laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The anti-D immunoglobulin market research report is one of a series of new reports from The Business Research Company that provides anti-D immunoglobulin market statistics, including anti-D immunoglobulin industry global market size, regional shares, competitors with a anti-D immunoglobulin market share, detailed anti-D immunoglobulin market segments, market trends and opportunities, and any further data you may need to thrive in the anti-D immunoglobulin industry. This anti-D immunoglobulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-D immunoglobulin market size has grown strongly in recent years. It will grow from $2.42 billion in 2024 to $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth observed during the historic period can be attributed to increasing awareness of rhesus incompatibility risks, the expansion of national immunization programs, implementation of maternal and neonatal health policies, rising global birth rates, and growth in blood transfusion procedures.

The anti-D immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to rising demand for antenatal and perinatal care, increased focus on maternal health in low- and middle-income countries, growing investments in healthcare infrastructure, expansion of universal health coverage programs, and regulatory support for immunoglobulin therapies. Major trends expected in this period include advancements in plasma fractionation technology, development of recombinant antibody alternatives, increased automation in immunoglobulin production, adoption of high-purity formulation techniques, and integration of cold chain monitoring systems.

The increasing global birth rates are expected to drive the growth of the anti-D immunoglobulin market in the future. Birth rates measure the number of live births per 1,000 people annually in a population. These rates are rising due to limited access to education and family planning services, leading to higher fertility rates and larger families. Anti-D immunoglobulin supports these birth rates by preventing Rh incompatibility during pregnancy, which lowers the risk of hemolytic disease in newborns and promotes healthier outcomes in subsequent pregnancies. For example, in April 2025, the Centers for Disease Control and Prevention, a US government agency, reported 3,622,673 births in 2024, marking a 1% increase compared to the previous year. Thus, the rising birth rates are fueling the expansion of the anti-D immunoglobulin market.

The growth of healthcare infrastructure is also expected to boost the anti-D immunoglobulin market going forward. Healthcare infrastructure encompasses the facilities, equipment, workforce, and support systems necessary to provide medical services to a population. The expansion of healthcare infrastructure is driven by the growing global population, which increases the demand for healthcare and necessitates the development of additional hospitals, clinics, and resources. Improved healthcare infrastructure enhances access to maternal care, facilitating better screening and timely administration of anti-D immunoglobulin to prevent hemolytic disease in newborns. For instance, in May 2023, the Department of Health and Social Care, a UK government department, announced plans to invest over $27 billion (£20 billion) in constructing new hospital facilities. Under the New Hospital Programme, two hospitals have been completed, five are under construction, and more than 20 are planned or in progress to be finished by the end of the following year. Therefore, the expanding healthcare infrastructure is contributing to the growth of the anti-D immunoglobulin market.

Leading companies in the anti-D immunoglobulin market are concentrating on innovative developments such as recombinant anti-D immunoglobulin to increase access to safe and reliable prophylaxis for Rh-negative pregnant individuals and enhance maternal health outcomes. Recombinant anti-D immunoglobulin is a laboratory-engineered monoclonal antibody designed to prevent Rh incompatibility in Rh-negative patients, providing an alternative to plasma-derived anti-D treatments with improved consistency, safety, and scalability. For example, in January 2022, Bharat Serums and Vaccines (BSV), an India-based biopharmaceutical company, launched the world's first marketed recombinant anti-Rho (D) immunoglobulin. This product offers a scientifically advanced approach to Rh prophylaxis by using recombinant technology, which improves product reliability and reduces variability seen in plasma-derived options. Its availability is especially important in regions with a high prevalence of Rh-negative pregnancies, where it can enhance preventive care and lower the risk of hemolytic disease in newborns.

Major players in the anti-d immunoglobulin market are Merck Group, Bayer AG, CSL Behring, Baxter International Inc., Intas Pharmaceuticals Ltd., Octapharma AG, Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kedrion Biopharma Inc., Biotest AG, Sanquin, Taj Pharmaceuticals Limited, Kamada Pharmaceuticals, Bharat Serums and Vaccines Limited, Saol Therapeutics Inc., Aetos Pharma Private Limited, Avin Darou, PV Pharma Healthcare Pvt. Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Ocean Pharmacoat Pvt. Ltd.

North America was the largest region in the anti-D immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-D immunoglobulin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-D immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-D immunoglobulin market consists of sales of hepatitis B immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, and varicella-zoster immunoglobulin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-D Immunoglobulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-d immunoglobulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for anti-d immunoglobulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-d immunoglobulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Anti-D Immunoglobulin Market Characteristics

3. Anti-D Immunoglobulin Market Trends And Strategies

4. Anti-D Immunoglobulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anti-D Immunoglobulin Growth Analysis And Strategic Analysis Framework

6. Anti-D Immunoglobulin Market Segmentation

7. Anti-D Immunoglobulin Market Regional And Country Analysis

8. Asia-Pacific Anti-D Immunoglobulin Market

9. China Anti-D Immunoglobulin Market

10. India Anti-D Immunoglobulin Market

11. Japan Anti-D Immunoglobulin Market

12. Australia Anti-D Immunoglobulin Market

13. Indonesia Anti-D Immunoglobulin Market

14. South Korea Anti-D Immunoglobulin Market

15. Western Europe Anti-D Immunoglobulin Market

16. UK Anti-D Immunoglobulin Market

17. Germany Anti-D Immunoglobulin Market

18. France Anti-D Immunoglobulin Market

19. Italy Anti-D Immunoglobulin Market

20. Spain Anti-D Immunoglobulin Market

21. Eastern Europe Anti-D Immunoglobulin Market

22. Russia Anti-D Immunoglobulin Market

23. North America Anti-D Immunoglobulin Market

24. USA Anti-D Immunoglobulin Market

25. Canada Anti-D Immunoglobulin Market

26. South America Anti-D Immunoglobulin Market

27. Brazil Anti-D Immunoglobulin Market

28. Middle East Anti-D Immunoglobulin Market

29. Africa Anti-D Immunoglobulin Market

30. Anti-D Immunoglobulin Market Competitive Landscape And Company Profiles

31. Anti-D Immunoglobulin Market Other Major And Innovative Companies

32. Global Anti-D Immunoglobulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-D Immunoglobulin Market

34. Recent Developments In The Anti-D Immunoglobulin Market

35. Anti-D Immunoglobulin Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기